This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stimpfl, M. Articles by Zeillinger, R. Search for Related Content PubMed PubMed Citation Articles by Stimpfl, M. Articles by Zeillinger, R.

Vascular Endothelial Growth Factor Splice Variants and Their Prognostic Value in Breast and Ovarian Cancer

Division of Gynecology, Molecular Oncology Group, Department of Obstetrics and Gynecology, University of Vienna, A-1090 Vienna, Austria [M. S., D. T., B. F., E. S., A. O., S. L., R. Z.]; Ludwig Boltzmann Institute for Gynecological Oncology and Reproductive Medicine, A-1090 Vienna, Austria [B. F., S. L.]; and Queensland Centre for Gynaecological Cancer, Royal Brisbane Hospital, QLD 4029 Herston, Brisbane, Australia [A. O.]

Purpose: Vascular endothelial growth factor (VEGF) is a promotor for tumor angiogenesis, and is known to be elevated in breast and ovarian cancers. Through alternative splicing six VEGF isoforms were identified. We studied VEGF isoform expression in breast and ovarian cancer cell lines, as well as in breast carcinomas and ovarian tumors, and correlated the expression pattern with the in vitro invasiveness of the breast carcinoma cell lines and the clinicopathologic characteristics of the tumors.

Experimental Design: Reverse transcription-PCR and automated laser fluorescence fragment analysis were used to determine the expression of each splice variant. This method allowed the detection of all of the splice variants simultaneously, especially VEGF145 for the first time in tumor tissue.

Results: VEGF121 and VEGF165 were the most dominantly expressed variants in all of the tumor samples and cell lines investigated. VEGF145 was very weakly or not expressed in breast and ovarian cancers. Statistical analysis showed no correlation between VEGF splice variant expression in the tumors and histological type, differentiation grade, tumor size, Fédération Internationale des Gynaecologistes et Obstetristes, and nodal status from cancer patients. There was also no correlation between the invasive capacity of breast cell lines and VEGF isoform expression.

Conclusions: Even though expression levels of VEGF have been shown to be important for tumor invasion and progression, the present data indicate no relation of VEGF isoform pattern with invasion and progression.

This article has been cited by other articles:

				G. M. Tozer, S. Akerman, N. A. Cross, P. R. Barber, M. A. Bjorndahl, O. Greco, S. Harris, S. A. Hill, D. J. Honess, C. R. Ireson, et al. Blood Vessel Maturation and Response to Vascular-Disrupting Therapy in Single Vascular Endothelial Growth Factor-A Isoform-Producing Tumors Cancer Res., April 1, 2008; 68(7): 2301 - 2311. [Abstract] [Full Text] [PDF]

				J. Gutierrez, G. E. Konecny, K. Hong, A. Burges, T. D. Henry, P. D. Lambiase, W. Lee Wong, and Y. G. Meng A New ELISA for Use in a 3-ELISA System to Assess Concentrations of VEGF Splice Variants and VEGF110 in Ovarian Cancer Tumors Clin. Chem., March 1, 2008; 54(3): 597 - 601. [Abstract] [Full Text] [PDF]

				A. Matsuda, S. Fukuda, K. Matsumoto, and H. Saito Th1/Th2 Cytokines Reciprocally Regulate In Vitro Pulmonary Angiogenesis via CXC Chemokine Synthesis Am. J. Respir. Cell Mol. Biol., February 1, 2008; 38(2): 168 - 175. [Abstract] [Full Text] [PDF]

				D. Cervi, Y. Shaked, M. Haeri, T. Usenko, C. R. Lee, J. J. Haigh, A. Nagy, R. S. Kerbel, E. Yefenof, and Y. Ben-David Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia Blood, March 1, 2007; 109(5): 2139 - 2146. [Abstract] [Full Text] [PDF]

				L. Milani, M. Fredriksson, and A.-C. Syvanen Detection of Alternatively Spliced Transcripts in Leukemia Cell Lines by Minisequencing on Microarrays Clin. Chem., February 1, 2006; 52(2): 202 - 211. [Abstract] [Full Text] [PDF]

				E. Zygalaki, A. Stathopoulou, C. Kroupis, L. Kaklamanis, Z. Kyriakides, D. Kremastinos, and E. S. Lianidou Real-Time Reverse Transcription-PCR Quantification of Vascular Endothelial Growth Factor Splice Variants Clin. Chem., August 1, 2005; 51(8): 1518 - 1520. [Full Text] [PDF]

				B. Diesel, J. Radermacher, M. Bureik, R. Bernhardt, M. Seifert, J. Reichrath, U. Fischer, and E. Meese Vitamin D3 Metabolism in Human Glioblastoma Multiforme: Functionality of CYP27B1 Splice Variants, Metabolism of Calcidiol, and Effect of Calcitriol Clin. Cancer Res., August 1, 2005; 11(15): 5370 - 5380. [Abstract] [Full Text] [PDF]

				T. Suganuma, K. Ino, K. Shibata, H. Kajiyama, T. Nagasaka, S. Mizutani, and F. Kikkawa Functional Expression of the Angiotensin II Type1 Receptor in Human Ovarian Carcinoma Cells and Its Blockade Therapy Resulting in Suppression of Tumor Invasion, Angiogenesis, and Peritoneal Dissemination Clin. Cancer Res., April 1, 2005; 11(7): 2686 - 2694. [Abstract] [Full Text] [PDF]

				K. E. Hamden, P. W. Ford, A. G. Whitman, O. F. Dyson, S.-Y. Cheng, J. A. McCubrey, and S. M. Akula Raf-Induced Vascular Endothelial Growth Factor Augments Kaposi's Sarcoma-Associated Herpesvirus Infection J. Virol., December 1, 2004; 78(23): 13381 - 13390. [Abstract] [Full Text] [PDF]

				S. Bornes, M. Boulard, C. Hieblot, C. Zanibellato, J. S. Iacovoni, H. Prats, and C. Touriol Control of the Vascular Endothelial Growth Factor Internal Ribosome Entry Site (IRES) Activity and Translation Initiation by Alternatively Spliced Coding Sequences J. Biol. Chem., April 30, 2004; 279(18): 18717 - 18726. [Abstract] [Full Text] [PDF]

				Y. Xing, A. Resch, and C. Lee The Multiassembly Problem: Reconstructing Multiple Transcript Isoforms From EST Fragment Mixtures Genome Res., March 1, 2004; 14(3): 426 - 441. [Abstract] [Full Text] [PDF]

				G. E. Konecny, Y. G. Meng, M. Untch, H.-J. Wang, I. Bauerfeind, M. Epstein, P. Stieber, J.-M. Vernes, J. Gutierrez, K. Hong, et al. Association between HER-2/neu and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients Clin. Cancer Res., March 1, 2004; 10(5): 1706 - 1716. [Abstract] [Full Text] [PDF]

				Z. Wang, H. S. Lo, H. Yang, S. Gere, Y. Hu, K. H. Buetow, and M. P. Lee Computational Analysis and Experimental Validation of Tumor-associated Alternative RNA Splicing in Human Cancer Cancer Res., February 1, 2003; 63(3): 655 - 657. [Abstract] [Full Text] [PDF]